Drugs / Phentermine
Phentermine
also known as
PHEN · 2-methyl-1-phenylpropan-2-amine · Adipex-p · Duromine · Fastin · Fentermina · Ionamin · Lomaira · +20 more
Small molecule targets SLC6A2
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Qsiva | — | 2013-05-14 | europa.eu ↗ |
| Approved | US (FDA) | FASTIN | — | 1973-08-14 | fda.gov ↗ |
Trials 41 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04881799 | Jul 2022 → Oct 2025 overdue | — | University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT02553824 | Oct 2015 → Feb 2017 | binge eating disorder, bulimia nervosa | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT02239913 | Sep 2014 → Sep 2019 | substance-related disorder | University of Kentucky | Completed | No outcome recorded |
| Phase 1 | NCT01500018 | Jan → Apr 2012 | substance abuse | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT00842400 | Feb → Mar 2009 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT00768404 | Oct 2008 → Mar 2009 | impaired renal function disease | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT00768209 | Oct 2008 → Mar 2009 | — | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT00518466 | Jul → Sep 2007 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00745251 | Aug 2008 → Sep 2009 | sleep apnea syndrome | VIVUS LLC | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07282340 | Jun 2026 → Jan 2028 expected | — | Russell McCulloh, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT06299891 | Mar 2025 → Feb 2026 overdue | acquired hypothalamic obesity, craniopharyngioma, hypothalamic neoplasm | Seattle Children's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05834062 | Oct 2023 → Aug 2026 | — | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT04572217 | Jun 2022 | — | Janey Pratt | Withdrawn | No outcome recorded |
| Phase 2 | NCT04621929 | Mar 2021 → Nov 2024 | obesity disorder, prediabetes syndrome, type 2 diabetes mellitus, urolithiasis | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT04721873 | Dec 2020 → Jun 2024 overdue | obesity disorder, ulcerative colitis | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 2 | NCT04095104 | Jan 2020 → Jan 2022 | morbid obesity | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT04007393 | Nov 2019 → Mar 2025 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02301416 | Dec 2014 → Jun 2018 | obesity disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02243202 | Sep 2014 → Jun 2015 | obesity disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01950520 | Feb 2014 → Dec 2022 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00806260 | Dec 2008 → May 2009 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 2 | NCT00737633 | Aug 2008 → Mar 2009 | type 2 diabetes mellitus | VIVUS LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00600067 | Jan → Nov 2008 | type 2 diabetes mellitus | VIVUS LLC | Completed | No outcome recorded |
| Phase 2 | NCT00486291 | Jun 2007 → Apr 2008 | type 2 diabetes mellitus | VIVUS LLC | Completed | No outcome recorded |
| Phase 2 | NCT00402077 | Nov 2006 → Aug 2007 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00000506 | May 1983 → Apr 1988 | heart disorder, obesity disorder, vascular disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00796367 | Dec 2008 → Jun 2010 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 3 | NCT00553787 | Nov 2007 → Jun 2009 | obesity disorder, type 2 diabetes mellitus | VIVUS LLC | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07213466 | Jan 2026 → Feb 2028 expected | bipolar I disorder, bipolar II disorder, obesity disorder, schizoaffective disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06854614 | Mar 2025 → Apr 2027 expected | obesity disorder | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05975580 | Aug 2023 → Jul 2027 expected | obesity disorder | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 4 | NCT05176626 | Jun 2022 → Dec 2026 expected | obesity disorder | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04614545 | Jan → Aug 2021 | obesity disorder | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03922945 | May 2019 → Apr 2021 | — | VIVUS LLC | Completed | No outcome recorded |
| Phase 4 | NCT03799198 | Jan 2019 → May 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT02229214 | Aug → Nov 2014 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 4 | NCT01922934 | Jan 2014 → Aug 2016 | obesity disorder | Denver Health and Hospital Authority | Completed | No outcome recorded |
| Phase 4 | NCT01987427 | Oct 2013 → Aug 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01834404 | Apr 2013 → Mar 2014 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01886937 | Jul 2012 → Jun 2014 | obesity disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00771654 | Feb 2009 → Sep 2010 | obesity disorder | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01719185 Background | Sep 2012 → Jan 2013 | hypertensive disorder, obesity disorder | Dr. Michael Lang | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03152123 Comparator | Mar → Oct 2017 | substance abuse | Bioprojet | Completed | No outcome recorded |
| Phase 1 | NCT02609477 Comparator | Jan → Jul 2016 | substance abuse | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04298203 Comparator | Aug 2021 → May 2026 | obesity disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03374956 Comparator | Dec 2017 → May 2022 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT02635386 Comparator | Mar 2016 → Jul 2020 | obesity disorder, polycystic ovary syndrome | Woman's | Completed | No outcome recorded |
| Phase 3 | NCT00563368 Comparator | Dec 2007 → Sep 2008 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 3 | NCT00554216 Comparator | Nov 2007 → May 2009 | obesity disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07058155 Comparator | Dec 2025 → Feb 2029 expected | cirrhosis of liver, morbid obesity, portal hypertension | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06768320 Comparator | Dec 2025 → Jan 2027 | obesity disorder | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 4 | NCT05215418 Comparator | Jan 2022 → Apr 2023 | hypertensive disorder | VIVUS LLC | Completed | No outcome recorded |
| Phase 4 | NCT04408586 Comparator | Jun 2020 → Jun 2022 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03779048 Comparator | Jul 2019 → May 2022 | obesity disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT03849729 Comparator | Mar 2018 → Apr 2020 | NAFLD1, morbid obesity | Hospital Juarez de Mexico | Completed | No outcome recorded |
| Phase 4 | NCT02911818 Comparator | Sep 2016 → Nov 2018 | obesity disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03675191 Background | Oct 2018 → Jul 2019 | obesity disorder | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT01616082 Comparator | Sep 2011 → Nov 2012 | metabolic disease, obesity disorder | AdventHealth Translational Research Institute | Completed | No outcome recorded |
| — | NCT01402674 Comparator | Aug 2011 → Nov 2012 | obesity disorder | Center for Weight Management, California | Completed | No outcome recorded |
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 61 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | phentermine | “Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily...” NCT00806260 ↗56“This study will test the use of phentermine and topiramate compared with placebo in helping adolescents who are at high risk for developing obesity to lose weight” NCT05834062 ↗ “Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine.” NCT07058155 ↗ “Istradefylline 40 mg, Istradefylline 80 mg, Istradefylline 160 mg, Phentermine 45 mg, Phentermine 90 mg, Placebo” NCT02609477 ↗ “Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks” NCT00737633 ↗ “VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days” NCT00842400 ↗ “Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)” NCT01950520 ↗ “VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule” NCT03922945 ↗ “7.5 mg phentermine/46 mg controlled-release topiramate” PMID 22158731 ↗ Dec 2011 “Phentermine or phentermine-topiramate (Qsymia)” NCT01922934 ↗ “VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)” NCT02229214 ↗ “phentermine 7·5 mg plus topiramate 46·0 mg” PMID 21481449 ↗ Apr 2011 “15 mg Phentermine and 92 mg Topiramate” NCT00745251 ↗ “3.75 mg phentermine/23 mg topiramate” NCT00554216 ↗ “phentermine 15mg/topiramate 100mg” NCT00486291 ↗ |
| Known as | 2-methyl-1-phenylpropan-2-amine | “Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine” NCT05975580 ↗ |
| Known as | Adipex-p | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Duromine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Fastin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Fentermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Ionamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Lomaira | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06768320 ↗ |
| Known as | NSC-44090 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | NSC-759163 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Obestin-30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Oby-trim | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Ona-mast | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | PHEN | “The safety and efficacy of treatment with phentermine
(PHEN)/topiramate (TPM) extended release (ER) plus lifestyle modification for weight loss and glycemic benefits were...” PMID 25249652 ↗ Sep 20141“initially randomized in a 3:3:2 ratio to daily treatment with topiramate (TPM) or phentermine (PHEN) or placebo” NCT05975580 ↗ |
| Known as | Phentermine component of qsymia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine Hydrochloride | “Phentermine Hydrochloride 8 MG” NCT05176626 ↗ |
| Known as | Phentermine hydrochloride civ | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine hydrochloride component of qsymia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine resin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine resin 30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine resin complex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Phentermine/topiramate extended-release | “Phentermine/topiramate extended-release (Qsymia® pills, p.o.)” NCT03799198 ↗ |
| Known as | Qsiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Qsymia | “Phentermine/topiramate extended-release (Qsymia® pills, p.o.)” NCT03799198 ↗ |
| Known as | Suprenza | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Tora | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Wilpo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Known as | Zantryl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1574 ↗ |
| Action | Inhibit | “reducing appetite through inhibition of norepinephrine reuptake (phentermine)” NCT04298203 ↗ |
| Modality | Small molecule | “Phentermine, an amphetamine congener, is the most widely used anti-obesity drug in the U.S.” NCT01402674 ↗ |
| Route | Oral | “oral tablet” NCT00402077 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter releasing agent” CHEMBL1574 ↗ |